RESEARCH TRIANGLE PARK, NC, Nov. 5, 2020 — Pappas Capital, a leading venture capital firm focused on advancing life sciences, today announced that its portfolio company, VelosBio Inc. (“VelosBio” or the...
Peninsula Pharmaceutical’s lead product, doripenem, was approved by the FDA in 2007 – about two years after Peninsula was acquired by Johnson & Johnson for approximately $250 million. At the time of that transaction, Peninsula had initiated six Phase 3 clinical trials with doripenem, a broad-spectrum antibiotic aimed at treating hospital-acquired pneumonia, complicated urinary tract infection and other intra-abdominal infections.
Peninsula Pharmaceuticals
Alameda, CA
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.